Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06870487 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 4
- Study locations
NCT06870487 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 6 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06870487, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body). The study has three parts: * Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymphomas (cancer that begins in cells of the immune system) and in participants with certain solid tumors whose disease has worsened on or after standard treatments. * Part B will test PF-08046032 (at selected doses) and sasanlimab in participants with certain solid tumors, including those whose disease has worsened on or after standard treatments as well as participants before receiving standard treatments. * Part C will further test the combination of PF-08046032 and sasanlimab in participants with specific types of solid tumors based on the results from Part A and Part B of the study. All participants will receive the study drug PF-08046032. Only participants in Part B and Part C of the study will also receive sasanlimab. PF-08046032 will be given as an intravenous (IV) infusion, which means it will be injected directly into a vein. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin.
Conditions Studied
Interventions
- DRUG Sasanlimab
- DRUG PF-08046032
Study Locations (4)
Washington
- Fred Hutchinson Cancer Center. - Seattle
- University of Washington Medical Center- Montlake - Seattle
Texas
- NEXT Oncology - San Antonio
Other
- Hospital Universitario Fundación Jiménez Díaz - Madrid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2026-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06870487
The ClinicalTrials.gov registry entry for NCT06870487 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sasanlimab is the first listed.
NCT06870487 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Washington, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06870487 about?
NCT06870487 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers". The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid t...
What is the current status of trial NCT06870487?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-05-08. Estimated completion is 2026-02-27.
What conditions does trial NCT06870487 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT06870487?
The interventions under investigation include: Sasanlimab (DRUG), PF-08046032 (DRUG).
Who is sponsoring clinical trial NCT06870487?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06870487 being conducted?
This trial has 4 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.